Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 99INDUSTRY 31OTHER_GOV 5UNKNOWN 3

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Stomach Neoplasms 1Metastatic Gastroesophageal Junction Adenocarcinoma 1MSS Metastatic Colorectal Cancer 1Gastric/Gastroesophageal Junction Adenocarcinoma 1Colonic Neoplasms 1

Interventions

Cisplatin 50Capecitabine 42apatinib 34Radiotherapy 33Oxaliplatin 33Gemcitabine 33Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 21Nivolumab 19pembrolizumab 18fludarabine 18Radiation 16Metformin 16Exercise 16camrelizumab 15S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER_GOV × HMPL-013 × Clear all
NCT05177068 2025-10-02

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Henan Cancer Hospital

Phase 2 Active not recruiting
42 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06329973 2025-07-17

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Henan Cancer Hospital

Phase 1/2 Recruiting
70 enrolled
Gastrointestinal

Metastatic Gastroesophageal Junction Adenocarcinoma

NCT06774222 2025-01-14

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

Henan Cancer Hospital

Phase 2 Recruiting
69 enrolled
Gastrointestinal

Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06613113 2024-09-25

Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

Ningbo Medical Center Lihuili Hospital

Phase NA Recruiting
30 enrolled
Gastrointestinal

MSS Metastatic Colorectal Cancer

NCT06218888 2024-01-23

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Fujian Cancer Hospital

Phase 2 Not yet recruiting
17 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡